215 related articles for article (PubMed ID: 34870237)
1. Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms.
Lehtiö J; Arslan T; Siavelis I; Pan Y; Socciarelli F; Berkovska O; Umer HM; Mermelekas G; Pirmoradian M; Jönsson M; Brunnström H; Brustugun OT; Purohit KP; Cunningham R; Foroughi Asl H; Isaksson S; Arbajian E; Aine M; Karlsson A; Kotevska M; Gram Hansen C; Drageset Haakensen V; Helland Å; Tamborero D; Johansson HJ; Branca RM; Planck M; Staaf J; Orre LM
Nat Cancer; 2021 Nov; 2(11):1224-1242. PubMed ID: 34870237
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer proteogenomics characterization of tumor immunity.
Petralia F; Ma W; Yaron TM; Caruso FP; Tignor N; Wang JM; Charytonowicz D; Johnson JL; Huntsman EM; Marino GB; Calinawan A; Evangelista JE; Selvan ME; Chowdhury S; Rykunov D; Krek A; Song X; Turhan B; Christianson KE; Lewis DA; Deng EZ; Clarke DJB; Whiteaker JR; Kennedy JJ; Zhao L; Segura RL; Batra H; Raso MG; Parra ER; Soundararajan R; Tang X; Li Y; Yi X; Satpathy S; Wang Y; Wiznerowicz M; González-Robles TJ; Iavarone A; Gosline SJC; Reva B; Robles AI; Nesvizhskii AI; Mani DR; Gillette MA; Klein RJ; Cieslik M; Zhang B; Paulovich AG; Sebra R; Gümüş ZH; Hostetter G; Fenyö D; Omenn GS; Cantley LC; Ma'ayan A; Lazar AJ; Ceccarelli M; Wang P;
Cell; 2024 Feb; 187(5):1255-1277.e27. PubMed ID: 38359819
[TBL] [Abstract][Full Text] [Related]
3. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
4. Current status of clinical proteogenomics in lung cancer.
Nishimura T; Nakamura H; Végvári Á; Marko-Varga G; Furuya N; Saji H
Expert Rev Proteomics; 2019 Sep; 16(9):761-772. PubMed ID: 31402712
[No Abstract] [Full Text] [Related]
5. Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer.
Luo YH; Yang YP; Chien CS; Yarmishyn AA; Adekunle Ishola A; Chien Y; Chen YM; Tsai PH; Lin TW; Wang ML; Chiou SH
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008490
[TBL] [Abstract][Full Text] [Related]
6. Multiplatform-based molecular subtypes of non-small-cell lung cancer.
Chen F; Zhang Y; Parra E; Rodriguez J; Behrens C; Akbani R; Lu Y; Kurie JM; Gibbons DL; Mills GB; Wistuba II; Creighton CJ
Oncogene; 2017 Mar; 36(10):1384-1393. PubMed ID: 27775076
[TBL] [Abstract][Full Text] [Related]
7. Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms.
Wang Y; Luo R; Zhang X; Xiang H; Yang B; Feng J; Deng M; Ran P; Sujie A; Zhang F; Zhu J; Tan S; Xie T; Chen P; Yu Z; Li Y; Jiang D; Zhang X; Zhao JY; Hou Y; Ding C
Nat Commun; 2023 Jan; 14(1):505. PubMed ID: 36720864
[TBL] [Abstract][Full Text] [Related]
8. Ultra High-plex Spatial Proteogenomic Investigation of Giant Cell Glioblastoma Multiforme Immune Infiltrates Reveals Distinct Protein and RNA Expression Profiles.
Bonnett SA; Rosenbloom AB; Ong GT; Conner M; Rininger ABE; Newhouse D; New F; Phan CQ; Ilcisin S; Sato H; Lyssand JS; Geiss G; Beechem JM
Cancer Res Commun; 2023 May; 3(5):763-779. PubMed ID: 37377888
[TBL] [Abstract][Full Text] [Related]
9. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.
Liu Q; Zhang J; Guo C; Wang M; Wang C; Yan Y; Sun L; Wang D; Zhang L; Yu H; Hou L; Wu C; Zhu Y; Jiang G; Zhu H; Zhou Y; Fang S; Zhang T; Hu L; Li J; Liu Y; Zhang H; Zhang B; Ding L; Robles AI; Rodriguez H; Gao D; Ji H; Zhou H; Zhang P
Cell; 2024 Jan; 187(1):184-203.e28. PubMed ID: 38181741
[TBL] [Abstract][Full Text] [Related]
10. SNF5 promotes cell proliferation and immune evasion in non-small cell lung cancer.
Chen Y; Zhao M; Shen D; Yi Q; Tang L
Bioengineered; 2022 May; 13(5):11530-11540. PubMed ID: 35506290
[TBL] [Abstract][Full Text] [Related]
11. Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways.
Soltis AR; Bateman NW; Liu J; Nguyen T; Franks TJ; Zhang X; Dalgard CL; Viollet C; Somiari S; Yan C; Zeman K; Skinner WJ; Lee JSH; Pollard HB; Turner C; Petricoin EF; Meerzaman D; Conrads TP; Hu H; ; Shriver CD; Moskaluk CA; Browning RF; Wilkerson MD
Cell Rep Med; 2022 Nov; 3(11):100819. PubMed ID: 36384096
[TBL] [Abstract][Full Text] [Related]
12. Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures.
Tanaka A; Ogawa M; Zhou Y; Namba K; Hendrickson RC; Miele MM; Li Z; Klimstra DS; Buckley PG; Gulcher J; Wang JY; Roehrl MHA
Cell Rep; 2024 Feb; 43(2):113810. PubMed ID: 38377004
[TBL] [Abstract][Full Text] [Related]
13. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
14. Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
Joshi SK; Piehowski P; Liu T; Gosline SJC; McDermott JE; Druker BJ; Traer E; Tyner JW; Agarwal A; Tognon CE; Rodland KD
Annu Rev Pharmacol Toxicol; 2024 Jan; 64():455-479. PubMed ID: 37738504
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.
Gao Y; Päivinen P; Tripathi S; Domènech-Moreno E; Wong IPL; Vaahtomeri K; Nagaraj AS; Talwelkar SS; Foretz M; Verschuren EW; Viollet B; Yan Y; Mäkelä TP
Clin Cancer Res; 2022 Jan; 28(1):227-237. PubMed ID: 34667030
[TBL] [Abstract][Full Text] [Related]
16. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
17. Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression.
Chen YJ; Roumeliotis TI; Chang YH; Chen CT; Han CL; Lin MH; Chen HW; Chang GC; Chang YL; Wu CT; Lin MW; Hsieh MS; Wang YT; Chen YR; Jonassen I; Ghavidel FZ; Lin ZS; Lin KT; Chen CW; Sheu PY; Hung CT; Huang KC; Yang HC; Lin PY; Yen TC; Lin YW; Wang JH; Raghav L; Lin CY; Chen YS; Wu PS; Lai CT; Weng SH; Su KY; Chang WH; Tsai PY; Robles AI; Rodriguez H; Hsiao YJ; Chang WH; Sung TY; Chen JS; Yu SL; Choudhary JS; Chen HY; Yang PC; Chen YJ
Cell; 2020 Jul; 182(1):226-244.e17. PubMed ID: 32649875
[TBL] [Abstract][Full Text] [Related]
18. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
19. An
Lin J; Liu J; Hao SG; Lan B; Zheng XB; Xiong JN; Zhang YQ; Gao X; Chen CB; Chen L; Huang YF; Luo H; Yi YT; Yi X; Lu JP; Zheng XW; Chen G; Wang XF; Chen Y
Front Immunol; 2022; 13():1022598. PubMed ID: 36505399
[TBL] [Abstract][Full Text] [Related]
20. Comparative proteogenomics profiling of non-small and small lung carcinoma cell lines using mass spectrometry.
Wu J; Hao Z; Ma C; Li P; Dang L; Sun S
PeerJ; 2020; 8():e8779. PubMed ID: 32351780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
